{"metadata":{"topics":["AMPA receptor","Acceleration","Access to information","Accountability","Accounting","Accounting standard","Active ingredient","Adverse effect","Advertising","Aid","Air pollution","Alberta","Allosteric regulation","Ampakine","Anatomical terms of location","Anti-competitive behaviour","Apnea","Applied ethics","Arbitration","Article Five of the United States Constitution","Article Four of the United States Constitution","Article One of the United States Constitution","Article Three of the United States Constitution","Article Two of the United States Constitution","Artificial neural network","Artificial objects","Assay","Asset","Asset purchase agreement","Attorney's fee","Audit","Author","Balance sheet","Bank","Bankruptcy","Barbados","Beneficial ownership","Bill (law)","Bill of sale","Biology","Blood","Board of directors","Bond (finance)","Brand","Breach of contract","Breathing","Broker","Business","Business economics","Business law","Business process","Business process management","Buyer","By-law","CX717","Canada","Capital (economics)","Case report","Case report form","Cash","Cause of action","Central sleep apnea","Change","Charter","Chemical compound","Chemical substance","Chemistry","Civil law (common law)","Civil law (legal system)","Clinical medicine","Clinical research","Clinical trial","Cognition","Cognitive science","Commercial general liability insurance","Common law","Common stock","Communication","Communication design","Companies","Company","Comparative law","Competition","Complaint","Computer","Computer program","Concealed carry in the United States","Concession (contract)","Confidentiality","Conflict of marriage laws","Consent","Consent decree","Consideration","Consolidation (business)","Constitution","Construction","Consultant","Contract","Contract law","Contractual term","Conveyancing","Cooperation","Copyright","Copyright infringement","Corporate finance","Corporate governance","Corporate jargon","Corporate law","Corporate personhood","Corporation","Corporations","Corruption","Cost","Counterclaim","Court","Covenant (law)","Credit","Creditor","Culture","Custom","Customs","Damages","Dangerous goods","Data","Debt","Decree","Deed","Definition","Delaware","Derivative (finance)","Design","Design patent","Development aid","Dietary supplement","Disability","Discovery (law)","Disease","Doctrines","Document","Documentary film","Documentation","Documents","Domain name","Dose (biochemistry)","Drawing","Drug discovery","Drugs","Duty of care","Economic sectors","Economics","Economics of regulation","Economy","Education","Efficacy","Emergence","Employment","Enantiomer","Encumbrance","Environmental law","Environmental protection","Environmental science","Equitable remedy","Equity (finance)","Equity (law)","Ethical principles","Ethically disputed business practices","Ethics","Ethics committee","Evaluation","Excise","Executive officer","Exercise","Existence","Expense","Experience","Exploitation of labour","Export","Fair market value","Federal Food, Drug, and Cosmetic Act","Federal Institute for Drugs and Medical Devices","Federal government of the United States","Fee","Fiduciary","Finance","Financial accounting","Financial adviser","Financial audit","Financial economics","Financial institution","Financial markets","Financial services","Financial statement","Financial statements","Financial transaction","Food","Food and Drug Administration","Forbearance","Force","Foreign Corrupt Practices Act","Form 8-K","Formula","France","Franchising","Fraud","Free base","Frequency","Future","Gender","Generally Accepted Accounting Principles (United States)","Generic drug","Germany","Glossary of patent law terms","Good faith","Good laboratory practice","Good manufacturing practice","Goods","Goods (economics)","Goodwill (accounting)","Government","Government agency","Government finances","Government information","Guarantee","Health","Health care","Health policy","Health research","Health sciences","Healthcare industry","Healthcare quality","High-throughput screening","Holiday","Hour","Human","Human activities","Human communication","Human rights","Hypothecation","Hypoventilation","Imperfect competition","Import","Income","Income tax","Indemnity","Indenture","Industrial wastewater treatment","Industries","Industry","Information","Information science","Inheritance","Injunction","Insolvency","Insurance","Insurance policy","Intangible asset","Intangible assets","Intangible property","Intellectual property","Intellectual property law","Intellectual works","Interest","Internal Revenue Code","Internal Revenue Service","Intravenous therapy","Invention","Inventor (patent)","Inventory","Investigational New Drug","Investment","Investment banking","Investor","Isomer","Issuer","Italy","Japan","Jargon","Joint venture","Judgment (law)","Judiciaries","Jurisdiction","Jurisprudence","Justice","Know-how","Knowledge","Lab notebook","Laboratory","Landscape","Last Judgment","Law","Law and economics","Law of obligations","Law of the United States","Lawsuit","Lawyer","Leadership","Lease","Legal communication","Legal concepts","Legal doctrines and principles","Legal documents","Legal ethics","Legal fictions","Legal liability","Legal literature","Legal remedy","Legal writing","Legislature","Letter of credit","Liability (financial accounting)","Liability insurance","License","Lien","Life sciences","Life sciences industry","Limited liability","Limited liability company","Local ordinance","Logo","Lung","Maintenance (technical)","Major depressive disorder","Major trauma","Management","Manufacturing","Market (economics)","Market value","Marketing","Mathematical optimization","Matter","Medical device","Medical humanities","Medical research","Medical specialties","Medical treatments","Medication","Medication package insert","Medicinal chemistry","Medicine","Medicines and Healthcare products Regulatory Agency","Mental disorder","Mergers and acquisitions","Metabolite","Metaphysics","Methodology","Microeconomics","Milestone","Misappropriation","Misrepresentation","Modulation","Molecule","Money","Monopoly (economics)","Moral rights","Morality","Mortgage law","Motor neuron","Muscle","Nationalization","Natural environment","Natural resource","Natural resources law","Negotiable instrument","Negotiation","Nervous system","Neurodegeneration","Neuron","New Drug Application","New York City","Non-compete clause","Non-disclosure agreement","Number","Obstructive sleep apnea","Occupational safety and health","Open government","Opinion","Option (finance)","Oral contract","Organization","Orphan drug","Out-of-pocket expense","Ownership","Packaging and labeling","Partnership","Patent","Patent Cooperation Treaty","Patent application","Patent attorney","Patent family","Patent infringement","Patent law","Patentability","Patient","Payment","Payments","Percentage","Personal property","Petroleum","Pharmaceutical formulation","Pharmaceutical industry","Pharmaceutical sciences","Pharmaceutics","Pharmacology","Pharmacovigilance","Pharmacy","Philosophy","Physical sciences","Planning permission","Policy","Political economy","Political science","Politics","Pollution","Possession (law)","Practice of law","Pre-clinical development","Preamble","Precedent","Preferred stock","Press release","Prevention","Preventive healthcare","Price","Pricing","Principles","Priority right","Privacy","Private law","Prodrug","Product","Product liability","Production and manufacturing","Products of chemical industry","Professional ethics","Profit (accounting)","Property","Property law","Proprietary software","Prosecutor","Provisional application","Psychological concepts","Public administration","Public domain","Public health","Public law","Public policy","Public records","Public sphere","Purchase order","Purchasing","Quality","Quorum","Real property","Reason","Reasonable person","Receipt","Receptor (biochemistry)","Recycling","Reduction to practice","Reexamination","Regent","Regents of the University of California","Regulation","Regulatory agency","Regulatory compliance","Reimbursement","Remittance","Renting","Repurchase agreement","Request for information","Research","Research and development","Resource","Revenue","Rhythm","Right of first refusal","Rights","Royalty payment","Rules","Safety","Sales","Salt (chemistry)","Sanitation","Science","Science and technology","Secretary of state","Section 23 of the Canadian Charter of Rights and Freedoms","Section 35 of the Constitution Act, 1982","Section 44 of the Constitution of Australia","Section 51 of the Constitution of Australia","Securities (finance)","Securities Exchange Act of 1934","Security (finance)","Security interest","Separation of powers","Serial code","Service industries","Services (economics)","Sexual dysfunction","Share (finance)","Shareholder","Sickle cell disease","Signature","Sleep","Sleep apnea","Sleep deprivation","Sleep disorder","Social Security (United States)","Social information processing","Social institutions","Social issues","Society","Sociological theories","Sources","Spain","Specification (technical standard)","Statute","Statute of limitations","Stock","Stock exchange","Stormwater","Subsidiary","Summons","Supplementary protection certificate","Supply chain management","Symbol","Table of contents","Tariff","Tax","Tax deduction","Tax return (United States)","Tax treaty","Technology","Theories of law","Therapy","Toxicity","Toxicology","Trade","Trade dress","Trade name","Trade secret","Trademark","Transport","Treaty","Trial","Tribunal","Trustee","U.S. Securities and Exchange Commission","Unemployment","United Kingdom","United States","United States dollar","United States patent law","University","University of Alberta","University of California","Urban, rural, and regional economics","Utility","Utility model","Value (ethics)","Value added","Vaso-occlusive crisis","Virtue","Waiver","Warranty","Waste","Waste management","Wastewater","Welfare","Wire transfer","Withholding tax","Word","Writ","Writing","Written communication"],"person_names":["article viii","maas","regents"],"vars":{"Party":{"Cortex Pharmaceuticals, Inc.":"[[Party 1]]"}},"organization_names":["acquired asset","acquired assets","acquired patent families","alberta ltd.","ampakine molecule","ampakine® pivotal studies","ampakine® trademark","applicable law","applicable law or governmental authorities","arzneimittel","biovail laboratories international srl","books and records","buyer confidential information","buyer of regulatory approval","commission","control","governmental authorities","governmental authority","intellectual property and books","intellectual property and books and records","nda submission","neurochemical modulation inc.","other ampakine®","other ampakine® compounds","patent families","primary ampakine","primary ampakine® compounds","primary contracts","seller compound activities","seller confidential information","seller intellectual property","seller know-how","seller or buyer","seller patent rights","seller recipient","seller resource employees","seller’s knowledge","state","sundays","united states federal food","uofa research consent"],"agreement_id":"85e53eebedf3f708c6623818a9428df45c6af81eaacaed249f23abf448a31935","terms":["***","*** comments received by Buyer and incorporate such comments to the extent practicable. With respect to the following contracts: (i) [***","*** of the Acquired Assets other than the Assumed Liabilities. All liabilities, obligations or commitments other than the Assumed Liabilities are referred to herein as the “***","*** publicly release consolidated financial results) provide Seller with [***","***.” Seller shall pay, perform and discharge when due, all of the Excluded Liabilities. Without limitation of the foregoing, the term “***","***CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***","***[***","***] (now known as [***","***] (the “***","***] Books and Records (and all tangible embodiments thereof) free and clear of all Liens other than contractual rights in favor of [***","***] Books and Records are no longer subject to confidentiality restrictions under the [***","***] Books and Records shall be excluded from Books and Records for so long as Seller is bound by the confidentiality restrictions pursuant to the [***","***] Seller agrees that, in the event that Buyer and its independent auditors (of nationally recognized standing in the U.S.) determine in good faith that Buyer or any one of its Affiliates is required (subsequent to the Effective Date) to consolidate Seller under US GAAP as a result of (i) [***","***] and the US Patent application [***","***] each occurrence and $[***","***] filed with the FDA on [***","***] from the date of the first commercial sale by Buyer or its Affiliate of a product that incorporates a Compound, neither Seller nor any of its Affiliates shall, directly or indirectly, develop, use or otherwise Exploit any compound or product in the Territory in the Field; *","***] hours in the aggregate for all Seller Resource Employees, then Buyer shall reimburse Seller for its reasonable, documented out-of-pocket expenses relating to such assistance at a rate of $[***","***] in the aggregate for Seller’s documented out-of-pocket expenses incurred in connection with the filing and prosecution of the Buyer 508 Application and the Buyer 254 Applications. If Buyer determines, in its sole discretion, to develop, use or otherwise Exploit either of the Compounds referred to as [***","***] milestone payable under the Patent Family 1 UofC License Agreement in connection with the compound referred to as [***","***] months of the Effective Date (the “***","***] on account of, and in connection with, [***","***] per occurrence and $[***","***] plus (A) [***","***]) retained by Seller relates to one or more Compounds and includes obligations of the other party to keep data or other information confidential, Seller shall enforce its rights with respect to such obligations for the benefit of Buyer. In the event that any contract (including, without limitation: (i) [***","***]) retained by Seller relates to one or more Compounds and includes provisions for publication of data or other information relating to such Compound(s), Seller shall not publish such data or other information without the prior written consent of Buyer and shall exercise its rights under such contract to prevent or limit any such publication by any other party thereto. In the event that any contract (including, without limitation, [***","***], as the case may be, at any time up to and including the Effective Date for a period up to and including [***","***], at any time up to and including the Effective Date for a period up to and including [***","***], by and between [***","***], then at such time Buyer shall have the right to negotiate a license with Seller on customary terms to use the Patent Family 11 Applications in the Field in any injectable dosage formulation for such compound(s) only. At the time such license is granted, Seller shall assist Buyer in obtaining such quantities of the Compounds referred to as [***","***]; (iii) [***","***]; and (ii) [***","***]; and (v) [***","***“Primary Contracts”***","***”","***” means books, records, files (including data files) and documents (including research and development records) and correspondence relating solely to information under Patent Family 5 and for which Seller is subject to confidentiality restrictions pursuant to the [***","***” means that certain [***","***” means the lesser of (a) [***","***” means the sublicense granted by Seller to Buyer in the Seller License Agreement of Seller’s Intellectual Property rights in Patent Family 5 that are licensed to Seller pursuant to the [***","***”) [***","***”) for a minimum of [***","***”) in accordance with the transfer plan set forth on Schedule 5.10 (the “***","***”), in which case Seller or Buyer, as applicable, shall be liable for all Losses arising from such Indemnification Claim (subject to the Cap, as defined below). In no event shall the aggregate indemnification to be paid by Seller, on the one hand, or Buyer, on the other hand, for any indemnification obligations for Losses under Sections 8.2(a) or 8.3(a) exceed $[***","***”). At Buyer’s reasonable request, Seller shall provide technical assistance to the employees and contractors of Buyer and its Affiliates as may be reasonably required to ensure an efficient and orderly transfer of the Seller Intellectual Property and Books and Records to Buyer, including making available to Buyer those of Seller’s Employees with training and expertise relating to the Acquired Assets listed on Schedule 5.10 (the “***","**ADDITIONAL AGREEMENTS**","**ASSET PURCHASE AGREEMENT**","**CONDITIONS PRECEDENT**","**DEFINITIONS; INTERPRETATION**","**Exhibit 1  Certain Compound Definitions**","**INDEMNIFICATION**","**MISCELLANEOUS**","**NOW, THEREFORE**","**PURCHASE AND SALE**","**Page**","**RECITALS**","**REPRESENTATIONS AND WARRANTIES OF BUYER**","**REPRESENTATIONS AND WARRANTIES OF SELLER**","**REPURCHASE OF ASSETS**","**TABLE OF CONTENTS (Cont.)**","**TABLE OF CONTENTS**","**WHEREAS**","**[***","*Authority; Binding Agreements*","*Brokers*","*Confidential*","*Conflicts; Consents*","*Good Title; Sufficiency of Assets*","*Governmental Authorizations*","*Organization, Standing and Power*","*[Remainder of page intentionally left blank]*","*and provided further that*","*provided further*","*provided further, however,*","*provided that*","*provided*","*provided, however*","*provided, that,*","’ fees and expenses and costs and expenses of investigation) (collectively, “***Losses***”","’s Affiliates) possession or control as of the Effective Date together with all work-in-progress, packaging and all bulk active pharmaceutical ingredient related to CX717 and CX1942 owned by Seller (or its Affiliates, as applicable) as of the Effective Date, including that which is described on Schedule 2.2(a)(vi) (collectively, the “***Non-Clinical and Clinical Material***”","“***$***”","“***254 Application***”","“***508 Application***”","“***AMPAKINE® NDA Submission***”","“***AMPAKINE® Pivotal Studies***”","“***AMPAKINE® Trademark***”","“***Acquired Assets***”","“***Acquired Patent Families***”","“***Act***”","“***Action***”","“***Affiliate***”","“***Agreement***”","“***Ampakine Molecule***”","“***Applicable Law***”","“***Assumed Contracts***”","“***Assumed Liabilities***”","“***Basket***”","“***BfArM Approvals***”","“***Books and Records***”","“***Business Day***”","“***Buyer 254 Applications***”","“***Buyer 508 Application***”","“***Buyer Confidential Information***”","“***Buyer Patent Family 11 Applications***”","“***Buyer Recipient***”","“***Buyer***”","“***CX1739***”","“***CX1763***”","“***CX1942***”","“***CX717 IND***”","“***CX717***”","“***Cap***”","“***Code***”","“***Competing Compound***”","“***Compounds***”","“***Consent***”","“***Contracts***”","“***Control***”","“***Controlled***”","“***Controlled***” and “***Controlling***”","“***Controlling***”","“***Copyrights***”","“***Distribute***”","“***Distribution***”","“***Dollars***”","“***Effective Date***”","“***Employee***”","“***Environmental Law***”","“***Excluded Assets***”","“***Excluded Intellectual Property***”","“***Excluded Liabilities***”","“***Exploit***”","“***Exploitation***”","“***FDA***”","“***Field***”","“***Filing Date***”","“***First Milestone Event***”","“***First Milestone Payment***”","“***Good Manufacturing Practices***”","“***Governmental Authority***”","“***Hold Back Amount***”","“***Hold-Back Amount***”","“***IND***”","“***Improvement***”","“***Indemnification Claim***”","“***Indemnified Party***”","“***Indemnifying Party***”","“***Information and Inventions***”","“***Intellectual Property***”","“***Licensed Patent Families***”","“***Lien***”","“***Losses***”","“***MAA***”","“***MHRA Approvals***”","“***Marketing Authorization Application***”","“***Material Adverse Effect***”","“***Material Consent***”","“***Milestone Event***”","“***Milestone Payments***”","“***NDA***”","“***Non-Assignable Right***”","“***Non-Clinical and Clinical Material***”","“***Non-Compete Adjustment Trigger***”","“***Order***”","“***Other AMPAKINE® Compounds***”","“***Parties***”","“***Party***”","“***Patent Family 1 UofC License Agreement***”","“***Patent Family 1***”","“***Patent Family 11 Applications***”","“***Patent Family 5***”","“***Patent Family 6***”","“***Patent Family 9***”","“***Patents***”","“***Permits***”","“***Permitted Liens***”","“***Person***”","“***Phase III Clinical Study***”","“***Primary AMPAKINE® Compounds***”","“***Primary Contract***”","“***Purchase Price***”","“***RD***”","“***Regulatory Approval***”","“***Regulatory Documentation***”","“***Related Contract***”","“***Related Contracts***”","“***Related Contracts***” and, collectively with the Primary Contracts, the “***Contracts***”","“***Related Documents***”","“***Representatives***”","“***SA***”","“***Second Milestone Event***”","“***Second Milestone Payment***”","“***Seller 254 Applications***”","“***Seller 508 Application***”","“***Seller Compound Activities***”","“***Seller Confidential Information***”","“***Seller Intellectual Property***”","“***Seller Know-How***”","“***Seller License Agreement***”","“***Seller Patent Rights***”","“***Seller Recipient***”","“***Seller Resource Employees***”","“***Seller***”","“***Seller’s Knowledge***”","“***Sleep Apnea***”","“***Subsidiary***”","“***Tax Return***”","“***Tax***”","“***Taxes***”","“***Territory***”","“***Third Milestone Event***”","“***Third Milestone Payment***”","“***Trademark***”","“***Transfer Date***”","“***Transfer Period***”","“***Transfer Plan***”","“***Transfer Taxes***”","“***US GAAP***”","“***UofA Consent and Amendment***”","“***UofA License Agreement***”","“***UofA Research Agreement***”","“***UofA Research Consent***”","“***UofC Field-Limited Agreement***”","“***UofC Intellectual Property***”","“***[***","“***[***]***”"]}}